Sparian Biosciences Initiates Phase 1 Trial of SBS-147, Novel Oral Pain Drug Targeting Opioid Alternative
核心洞察
Sparian Biosciences (搜索) has initiated a Phase 1 clinical trial of SBS-147, a next-generation oral arylepoxamide receptor (搜索) agonist designed to treat acute and chronic pain (搜索) without the respiratory depression and abuse liability associated with opioids.
Preclinical studies demonstrate that SBS-147 provides potent analgesia in both nociceptive and neuropathic pain (搜索) models with durable responses lasting up to 24 hours, positioning it as a potential opioid replacement therapy.
The Phase 1 SAD/MAD study and subsequent Phase 2 development are supported by a $15 million NIH/NIDA HEAL Initiative grant, representing the company's fifth NIH grant totaling $75 million in government funding.
Sparian Biosciences (搜索) has launched a Phase 1 clinical trial of SBS-147, a novel oral arylepoxamide receptor (搜索) (AEAr) agonist designed to address the critical need for effective pain management alternatives to opioids. The clinical-stage CNS-focused biopharmaceutical company announced the initiation of the study, which represents a significant advancement in developing non-opioid analgesics amid the ongoing opioid crisis.
Novel Mechanism Targets Pain Without Opioid Risks
SBS-147 represents the next generation of AEAr agonists, building upon the foundation established by the company's first-generation compound SBS-1000. The oral formulation expands potential therapeutic applications to include both acute and chronic pain (搜索) conditions, offering greater dosing flexibility compared to its parenteral predecessor.
"SBS-147 builds on the success of the first generation AEAr agonist, SBS-1000. The added dosing flexibility as an oral compound expands potential indications to include acute and chronic pain (搜索)," said Jeffrey B. Reich, MD, Chief Executive Officer of Sparian Biosciences (搜索).
Preclinical studies have demonstrated SBS-147's potent analgesic properties across multiple pain models. The compound showed efficacy in both nociceptive and neuropathic pain (搜索) models with durable responses extending to 24 hours. Critically, SBS-147 does not cause respiratory depression or demonstrate abuse liability when compared to opioids such as morphine, addressing two of the most serious safety concerns associated with current pain medications.
Phase 1 Trial Design and Objectives
The Phase 1 clinical trial will employ a combined single ascending dose (SAD) and multiple ascending dose (MAD) design to primarily evaluate the safety, tolerability, and pharmacokinetics of SBS-147 in healthy volunteers. This comprehensive approach will provide essential data on how the drug behaves in the human body and establish appropriate dosing parameters for future studies.
SBS-1000, the company's first-generation AEAr agonist, has already completed a Phase 1 single ascending dose study as a parenteral formulation and continues development for acute pain (搜索) applications, providing valuable precedent for the AEAr mechanism's clinical viability.
Substantial NIH Funding Supports Development
The development of SBS-147 from Phase 1 through Phase 2 is supported by a $15 million grant from the NIH/NIDA HEAL Initiative. This funding represents the fifth NIH/NIDA grant awarded to Sparian Biosciences (搜索), bringing the company's total government funding to $75 million across four therapeutic programs.
The HEAL (Help End Addiction Long Term) program was specifically created by Congress to advance promising drugs targeting substance use disorders, particularly opioid addiction. The substantial federal investment underscores the urgent need for innovative pain management solutions that can help address the opioid epidemic.
Addressing Critical Medical Need
"Effective pain management remains a significant challenge across medicine and surgery, and SBS-147 has the potential to replace opioids for the treatment of acute and chronic pain (搜索)," Dr. Reich explained. "In the face of the ongoing opioid crisis, we believe the AEAr agonists like SBS-147 and SBS-1000 could represent fundamental and critically needed innovation."
The company's approach addresses a substantial unmet medical need, as current pain management options often involve trade-offs between efficacy and safety. Traditional opioids, while effective for pain relief, carry significant risks including respiratory depression, addiction potential, and overdose risk.
Company Background and Pipeline
Sparian Biosciences (搜索) was co-founded by Jeffrey B. Reich, MD, and Gavril Pasternak, MD/PhD, and spun out of Memorial Sloan Kettering Cancer Center (MSK). The company maintains a focused pipeline of five programs addressing acute and chronic pain (搜索), opioid use disorder (搜索), opioid withdrawal syndrome (搜索), acute opioid overdose, and stimulant use disorder (搜索).
The research is supported by the National Institute on Drug Abuse (NIDA) HEAL Initiative of the National Institutes of Health under award number 1UG3DA064392-01. Memorial Sloan Kettering Cancer Center maintains financial interests in Sparian Biosciences (搜索).